PMID-34011034 – Thymosin Alpha-1 After Curative HCC Resection PSM
He L et al. "Thymosin alpha 1 improves overall survival after curative resection of hepatocellular carcinoma: A propensity score-matched analysis," Medicine, 2021;100(24):e26336.
Quick Reference
| Property | Value |
|---|---|
| PMID | 34011034 |
| DOI | N/A |
| Year | 2021 |
| Journal | Medicine |
| Study Type | Retrospective Observational with Propensity Score Matching |
| Evidence Level | III |
| Sample | n=468 HCC patients (234 matched pairs) |
| Peptide(s) Studied | Thymosin Alpha-1 |
Key Findings
- After propensity score matching (n=234 matched pairs), thymosin alpha-1 adjuvant therapy after curative HCC resection significantly improved both overall survival and recurrence-free survival
- Overall survival hazard ratio: HR = 0.308 (thymalfasin group), indicating a 69.2% reduction in risk of death
- Recurrence-free survival hazard ratio: HR = 0.381, indicating a 61.9% reduction in risk of recurrence
- The magnitude of benefit was remarkably large and statistically robust even after propensity score matching eliminated baseline imbalances
- Subgroup analyses showed consistent benefit across tumor sizes, AFP levels, and disease stages
- Thymosin alpha-1 enhanced post-operative immune reconstitution, with improved lymphocyte subsets in the treatment group
Study Design
Retrospective cohort study with propensity score matching to reduce selection bias. From a larger cohort of HCC patients undergoing curative hepatectomy, 234 patients receiving adjuvant thymosin alpha-1 were matched 1:1 with 234 controls based on age, sex, tumor characteristics, liver function, and surgical factors. Primary endpoints were overall survival and recurrence-free survival.
Limitations
- Despite propensity score matching, unmeasured confounders may persist (inherent limitation of retrospective design)
- Single-center study from a Chinese institution, where HBV-related HCC predominates — may not generalize to HCV- or NAFLD-related HCC populations
- The effect sizes (HR 0.308 for OS, HR 0.381 for RFS) are unusually large for an adjuvant immunotherapy, warranting cautious interpretation and replication
- Thymosin alpha-1 dosing regimen not standardized across the cohort
- No comparison with other adjuvant immunotherapies (e.g., checkpoint inhibitors)
Clinical Relevance
This propensity score-matched analysis provides stronger evidence than unmatched retrospective studies for the survival benefit of adjuvant thymosin alpha-1 after curative HCC resection. The effect sizes are remarkable — HR 0.308 for OS and 0.381 for RFS — though their magnitude warrants cautious interpretation pending prospective validation. Combined with the TACE+thymalfasin RCT data (PMID-19669251) and the earlier retrospective study (PMID-28422855), a consistent pattern emerges supporting thymosin alpha-1 in HCC management across disease stages.
Related
#research #observational #evidence-level-III #cancer